NIH Reporter #11255601

Preclinical efficacy of AST-004 as a treatment for substance use disorder

This award funds a preclinical study to evaluate AST-004 as a treatment for substance use disorder, focusing on its effects on cocaine and methamphetamine behaviors in rodents, involving multiple research institutions.

Description

The project involves assessing oral AST-004’s potential to attenuate cocaine and methamphetamine self-administration and seeking in two rodent species. The project is a collaboration between Astrocyte Pharmaceuticals, Inc., the University of Texas San Antonio, and the Oklahoma Medical Research Foundation. The project aims to establish the efficacy and translational potential of AST-004 as a treatment for substance use disorder. The project includes exploring effects on cocaine and methamphetamine self-administration, seeking, and non-specific effects on food self-administration, anxiety, and sucrose preference.

View original record